The investment case as a mechanism for addressing the NCD burden: Evaluating the NCD institutional context in Jamaica, and the return on investment of select interventions
Autoři:
Brian Hutchinson aff001; Roy Small aff002; Kofi Acquah aff003; Rosa Sandoval aff004; Rachel Nugent aff001; Delia Itziar Belausteguigoitia aff004; Nicholas Banatvala aff005; Douglas Webb aff002; Dudley Tarlton aff006; Alexey Kulikov aff005; Elisa Prieto aff007; Karin Santi aff008
Působiště autorů:
Center for Noncommunicable Diseases, RTI International, Seattle, Washington, United States of America
aff001; HIV, Health and Development Group, United Nations Development Programme, New York, New York, United States of America
aff002; Social Policy, Health and Economics Research (SPHERE), RTI International, Research Triangle Park, North Carolina, United States of America
aff003; Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., United States of America
aff004; UN Interagency Task Force on the Prevention and Control of Noncommunicable Diseases, World Health Organization, United Nations, Geneva, Switzerland
aff005; Bureau Policy and Programme Support, United Nations Development Programme, New York, New York, United States of America
aff006; Noncommunicable Diseases and Mental Health, Caribbean Subregional Program Coordination, Pan American Health Organization, Bridgetown, Barbados
aff007; HIV, Health and Development Group, United Nations Development Programme, Panama City, Panama
aff008
Vyšlo v časopise:
PLoS ONE 14(10)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0223412
Souhrn
Noncommunicable diseases (NCDs) are a broad challenge for decision-makers. NCDs account for seven out of every 10 deaths globally, with 42 percent occurring prematurely in individuals under age 70. Despite their heavy toll, NCDs are underfunded, with only around two percent of global funding dedicated to the disease set. Country governments are responsible for funding targeted actions to reduce the NCD burden, but among other priorities, many have yet to invest in the health-system interventions and policy measures that can reduce the burden. This article examines “investment cases” as a potential mechanism for catalyzing attention to—and funding for—NCDs. In Jamaica, using the UN inter-agency OneHealth Tool, we conducted an economic analysis to estimate the return-on-investment from scaling up strategic clinical interventions, and from implementing or intensifying policy measures that target NCD risk factors. In addition, we conducted an institutional and context (ICA) analysis, interviewing stakeholders across sectors to take stock of promising policy pathways (e.g., areas of general consensus, political appetite and opportunity) as well as challenges to implementation. The economic analysis found that scaling up clinical interventions that target CVD, diabetes, and mental health disorders, and policy measures that target tobacco and alcohol use, would save over 6,600 lives between 2017–2032, and avert JMD 81.3 billion (USD 640 million) in direct and indirect economic costs that result from mortality and morbidity linked to NCDs. The ICA uncovered government economic growth targets and social priorities that would be aided by increased attention to NCDs, and it linked these targets and priorities to the economic analysis.
Klíčová slova:
economic growth – Health economics – Economics – Finance – Health care policy – Economic analysis – Jamaica
Zdroje
1. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. Geneva, 2018.
2. Council on Foreign Relations. The emerging global health crisis: Noncommunicable diseases in low- and middle-income countries. Independent Task Force Report No. 722014.
3. World Health Organization. Global Health Estimates 2016: Disease burden by Cause, Age, Sex, by Country and by Region, 2000–2016. Geneva, 2018.
4. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017; 389 (10083): 1981–2004. Epub 2017/04/24. doi: 10.1016/S0140-6736(17)30874-7 28433256; PubMed Central PMCID: PMC5440770.
5. Resch S, Hecht R. Transitioning financial responsibility for health programs from external donors to developing countries: Key issues and recommendations for policy and research. J Glob Health. 8.
6. Health expenditure, public (% of total health expenditure). The World Bank Open Data.
7. Jamaica—NCD National Health Sub-accounts. 2012 2012. Report No.
8. Chaker L, Falla A, van der Lee SJ, Muka T, Imo D, Jaspers L, et al. The global impact of non-communicable diseases on macro-economic productivity: a systematic review. European journal of epidemiology. 2015;30(5):357–95. Epub 2015/04/04. doi: 10.1007/s10654-015-0026-5 25837965; PubMed Central PMCID: PMC4457808.
9. Anesetti-Rothermel A, Sambamoorthi U. Physical and mental illness burden: disability days among working adults. Popul Health Manag. 2011;14(5):223–30. Epub 2011/04/22. doi: 10.1089/pop.2010.0049 21506731.
10. Wang PS, Beck A, Berglund P, Leutzinger JA, Pronk N, Richling D, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45(12):1303–11. Epub 2003/12/11. doi: 10.1097/01.jom.0000100200.90573.df 14665817.
11. Bertram MY, Sweeny K, Lauer JA, Chisholm D, Sheehan P, Rasmussen B, et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018. Epub 2018/04/09. doi: 10.1016/s0140-6736(18)30665-2 29627159.
12. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. The lancet Psychiatry. 2016;3(5):415–24. Epub 2016/04/17. doi: 10.1016/S2215-0366(16)30024-4 27083119.
13. Stenberg K, Sweeny K, Axelson H, Temmerman M, Sheehan P. Returns on Investment in the Continuum of Care for Reproductive, Maternal, Newborn, and Child Health. 2016. https://www.ncbi.nlm.nih.gov/books/NBK361897/.
14. Current and historical rate tables online.: XE; n.d. Historical exchange rates—JMD—Jamaican Dollar]. Available from: https://www.xe.com/currencytables/?from=JMD&date=2016-07-01.
15. Economic Growth Council Secretariat. Economic Growth Council Call to Action—5 in 4. online: 2016.
16. Task Force on Fiscal Policy for Health. Health Taxes to Save Lives: Employing Effective Excise Taxes on Tobacco, Alcohol, and Sugary Beverages. New York: Bloomberg Philanthropies, 2019.
17. Colchero MA, Rivera-Dommarco J, Popkin BM, Ng SW. In Mexico, Evidence Of Sustained Consumer Response Two Years After Implementing A Sugar-Sweetened Beverage Tax. Health affairs (Project Hope). 2017;36(3):564–71. Epub 2017/02/24. doi: 10.1377/hlthaff.2016.1231 28228484; PubMed Central PMCID: PMC5442881.
18. Harriot A, Jones M. Crime and Violence in Jamaica. Inter-American Development Bank Institutions for Development and Country Department Caribbean Group, 2016 Contract No.: Technical Note No. IDB-TN-1060.
19. Editorial. How Much Has Crime Really Cost Jamaica? The Gleaner. 2016.
Článok vyšiel v časopise
PLOS One
2019 Číslo 10
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
- Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
- Experimentally validated simulation of coronary stents considering different dogboning ratios and asymmetric stent positioning
- Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis